Neoleukin Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NLTX research report →
Companywww.neoleukin.com
Neoleukin Therapeutics, Inc. , a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
- CEO
- Donna M. Cochener-Metcalfe
- IPO
- 2014
- Employees
- 7
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $8.20M
- P/E
- -0.79
- P/S
- 0.00
- P/B
- 0.33
- EV/EBITDA
- 1.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.88%
- ROIC
- -44.78%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-90,351,000 · -20.24%
- EPS
- $0.00 · 100.00%
- Op Income
- $-103,328,000
- FCF YoY
- -9.73%
Performance & Tape
- 52W High
- $18.80
- 52W Low
- $3.42
- 50D MA
- $13.83
- 200D MA
- $14.98
- Beta
- 1.10
- Avg Volume
- 5.52K
Get TickerSpark's AI analysis on NLTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 16, 24 | Woods Robert Keith | other | 15,400 |
| Jan 16, 24 | PALEKAR ROHAN | other | 15,400 |
| Jan 16, 24 | Noonberg Sarah B. | other | 15,400 |
| Jan 16, 24 | Freedland Cory S. | other | 15,400 |
| Jan 16, 24 | BAFFI ROBERT | other | 15,400 |
| Jan 16, 24 | Jordan Julie | other | 75,000 |
| Jan 16, 24 | Jordan Julie | other | 0 |
| Dec 18, 23 | Cvijic Christine Mikail | other | 0 |
| Dec 18, 23 | Cvijic Christine Mikail | other | 37,800 |
| Dec 18, 23 | Cvijic Christine Mikail | other | 29,453 |
Our NLTX Coverage
We haven't published any research on NLTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NLTX Report →